DUBLIN, May 19 /PRNewswire/ --
- Completed Series B Total Stands at EUR21.3 m
Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, today announced that Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3 million to the Series B financing announced in February this year, bringing the total round to EUR21.3 million. The new investors join Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba-Kernel in completing the round, which will enable Opsona to further expand its clinical development pipeline.
Proceeds will support the advancement of Opsona's clinical trials targeting inflammatory diseases such as rheumatoid arthritis, lupus and solid organ transplant rejection. It will also be used to improve Opsona's capability to clinically evaluate novel compounds for in-licensing aimed at treating autoimmune and inflammatory diseases.
Commenting on the announcement, Mark Heffernan, Chief Executive Officer of Opsona Therapeutics, said: "We are delighted by the calibre of investors who have supported our Series B financing. The investment by Roche Venture Fund is a further endorsement of Opsona's approach to targeting the innate immune system, and the continued support of Enterprise Ireland demonstrates their commitment to investment in high-potential companies. This completed
Series B round of EUR21.3 million places Opsona in a strong financial position, which will enable us to continue to achieve our clinical and operational goals over the next three years."
"Roche is excited about investing in Opsona," said Carole Nuechterlein,
Head of the Roche Venture Fund. "Opsona's scientific founder, Professor Luke
|SOURCE Opsona Therapeutics Ltd|
Copyright©2009 PR Newswire.
All rights reserved